Update on the management of cholangiocarcinoma

Digestive Diseases

Volumn 32, Issue 5, 2014, Pages 570-578

  Skipworth, J R A ^a   Keane, M G ^b   Pereira, S P ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adjuvant therapy; Biliary tract carcinoma; Cholangiocarcinoma; Neoadjuvant therapy; Surgery

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PLATINUM DERIVATIVE; SORAFENIB; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURGERY; CHEMOEMBOLIZATION; COMMON BILE DUCT; COMMON BILE DUCT OBSTRUCTION; ENDOSCOPY; EPITHELIUM; EXTERNAL BEAM RADIOTHERAPY; HEPATIC DUCT; HEPATOBILIARY SYSTEM; HUMAN; LIVER TRANSPLANTATION; NONHUMAN; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RARE DISEASE; RECURRENCE FREE SURVIVAL; ABLATION THERAPY; ADVANCED CANCER; ARTIFICIAL EMBOLISM; BIOLOGICAL THERAPY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHOLESTASIS; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONFOCAL MICROSCOPY; DECOMPRESSION SURGERY; ENDOSCOPIC BILIARY DECOMPRESSION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; LIVER RESECTION; LONG TERM SURVIVAL; MANAGED CARE; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); BILE DUCT NEOPLASMS; CANCER STAGING; CHOLANGIOCARCINOMA; INTRAHEPATIC BILE DUCT; METASTASIS; PATHOLOGY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 84904652805     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000360507     Document Type: Article

References (105)

1. Nakeeb A, et al: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224: 463-473; discussion 473-475.
2. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353- 1357.
3. Taylor-Robinson SD, et al: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820.
4. Endo I, et al: Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248: 84-96.
5. Khan SA, et al: Cholangiocarcinoma and its management. Gut 2007; 56: 1755-1756.
6. Khan SA, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51(suppl 6):VI1- VI9.
7. Khan SA, et al: Changing internationals trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806- 813.
8. Nehls O, Gregor M, Klump B: Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004; 24: 139-154.
9. Locker GY, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
10. Bonney GK, et al: Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 2008; 9: 149-158.
11. Meining A, et al: Direct visualization of indeterminate pancreaticobiliary strictures with probe-based confocal laser endomicroscopy: a multicentre experience. Gastrointest Endosc 2011; 74: 961-968.
12. Tischendorf JJ, et al: Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006; 38: 665-669.
13. Moreno Luna LE, et al.: Advanced cytologic techniques for the detection of malignant pancreobiliary strictures. Gastroenterology 2006; 131: 1064-1072.
14. Bismuth H, Nakache R, Diamond T: Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215: 31-38.
15. Witzigmann H, et al: Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg 2006; 244: 230-239.
16. Ito F, et al: Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 2008; 248: 273- 279.
17. Jarnagin WR, et al: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517; discussion 517-519.
18. Romagnuolo J, et al: Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139: 547-557.
19. Corvera CU, et al: 18 F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008; 206: 57-65.
20. Furukawa H, et al: Prognostic importance of standardized uptake value on 18 F-fluorodeoxyglucose- positron emission tomography in biliary tract carcinoma. J Surg Oncol 2009; 100: 494-499.
21. Baron TH, et al: A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004; 2: 214-219.
22. De Bellis M, et al: Tissue sampling at ERCP in suspected malignant biliary strictures (Part 1). Gastrointest Endosc 2002; 56: 552-561.
23. Moreno Luna LE, et al: Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006; 131: 1064-1072.
24. Harewood GC, et al: Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol 2004; 99: 1464-1469.
25. Meining A, et al: Detection of cholangiocarcinoma in vivo using miniprobe-based confocal fluorescence microscopy. Clin Gastroenterol Hepatol 2008; 6: 1057-1060.
26. Huggett MT, et al: Photodynamic therapy of pancreatic cancer and elastic scattering spectroscopy of the duodenal mucosa for the detection of pancreaticobiliary malignancy. Proc SPIE7886, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy, 2011. XX, 78860J.
27. Hoffman A, et al: Methylene blue-aided cholangioscopy in patients with biliary strictures: feasibility and outcome analysis. Endoscopy 2008; 40: 563-571.
28. Lu XL, Itoi T, Kubota K: Cholangioscopy by using narrow-band imaging and transpapillary radiotherapy for mucin-producing bile duct tumour. Clin Gastroenterol Hepatol 2009; 7:e34-e35.
29. Fritscher-Ravens A, et al: EUS-guided fineneedle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am J Gastroenterol 2004; 99: 45-51.
30. Goere D, et al: Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 2006; 20: 721-725.
31. Corvera CU, Weber SM, Jarnagin WR: Role of laparoscopy in the evaluation of biliary tract cancer. Surg Oncol Clin N Am 2002; 11: 877-891.
32. Grandadam S, et al: Role of preoperative optimization of the liver for resection in patients with hilar cholangiocarcinoma type III. Ann Surg Oncol 2010; 17: 3155-3161.
33. Pitt HA, et al: Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 1985; 201: 545-553.
34. Hatfield AR, et al: Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet 1982; 2: 896-899.
35. Blamey SL, et al: Prediction of risk in biliary surgery. Br J Surg 1983; 70: 535-538.
36. Hochwald SN, et al: Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999; 134: 261-266.
37. Mansfield SD, et al: Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome. World J Gastroenterol 2005; 11: 7625-7630.
38. Cortes A, et al: Effect of bile contamination on immediate outcomes after pancreaticoduodenectomy for tumor. J Am Coll Surg 2006; 202: 93-99.
39. Nagino M, et al: Preoperative biliary drainage for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008; 15: 25-30.
40. Nimura Y, et al: Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 2000; 7: 155-162.
41. Hemming AW, et al: Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003; 237: 686-691; discussion 691-693.
42. Abdalla EK, et al: Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137: 675-680; discussion 680-681.
43. Igami T, et al: Surgical treatment of hilar cholangiocarcinoma in the 'new era': the Nagoya University experience. J Hepatobiliary Pancreat Surg 2010; 17: 449-454.
44. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125.
45. Khan SA, et al: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-813.
46. Jarnagin WR, Shoup M: Surgical management of cholangiocarcinoma. Semin Liver Dis 2004; 24: 189-199.
47. Van den Broek MA, et al: Feasibility of randomized controlled trials in liver surgery using surgery-related mortality or morbidity as endpoint. Br J Surg 2009; 96: 1005-1014.
48. Gerhards MF, et al: Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma - a single-center experience. Surgery 2000; 127: 395-404.
49. Ebata T, et al: Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003; 238: 720-727.
50. Neuhaus P, et al: Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 2003; 388: 194- 200.
51. Su CH, et al: Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996; 223: 384-394.
52. Kondo S, et al: Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg 2004; 240: 95-101.
53. Schnitzbauer AA, et al: Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling two-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255: 405-414.
54. Knoefel WT, et al: In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection. Br J Surg 2013; 100: 388-394.
55. Nishio H, Nagino M, Nimura Y: Surgical management of hilar cholangiocarcinoma: the Nagoya experience. HPB (Oxford) 2005; 7: 259-262.
56. Hidalgo E, et al: Surgery for hilar cholangiocarcinoma: the Leeds experience. Eur J Surg Oncol 2008; 34: 787-794.
57. Silva MA, et al: Surgery for hilar cholangiocarcinoma; a 10-year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005; 31: 533-539.
58. Reding R, et al: Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey. Ann Surg 1991; 213: 236-241.
59. Aljiffry M, et al: Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 2009; 208: 134-147.
60. Henson DE, Albores-Saavedra J, Corle D: Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992; 70: 1498-1501.
61. Iwatsuki S, et al: Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187: 358-364.
62. Witzigmann H, et al: Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg 2006; 244: 230-239.
63. Rea DJ, et al: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-458; discussion 458- 461.
64. Rea DJ, et al: Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am 2009; 18: 325-337, ix.
65. Heimbach JK, et al: Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004; 24: 201-207.
66. Callery MP: Transplantation for cholangiocarcinoma: advance or supply-demand dilemma? Gastroenterology 2006; 130: 2242- 2244; discussion 2244.
67. Martin RC 2nd, et al: Cost comparison of endoscopic stenting versus surgical treatment for unresectable cholangiocarcinoma. Surg Endosc 2002; 16: 667-670.
68. Moss AC, Morris E, Leyden J, MacMathuna P: Malignant distal biliary obstruction: a systemic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 2007; 33: 213-221.
69. Krokidis M, et al: Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered wallstents. Cardiovasc Intervent Radiol 2010; 33: 97-106.
70. Isayama H, et al: A prospective randomised study of 'covered' versus 'uncovered' diamond stents for the management of distal malignant biliary obstruction. Gut 2004; 53: 729- 734.
71. Kullman E, et al: Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc 2010; 72: 915-923.
72. Kitano M, et al: Covered self-expanding metal stents with anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol 2013; 305: 1-10.
73. Perdue DG, et al: Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction: a prospective multicentre observational cohort study. J Clin Gastroenterol 2008; 42: 1040-1046.
74. Hintze RE, et al: Magnetic resonance cholangiopancreatography- guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc 2001; 53: 40-46.
75. Freeman ML, Overby C: Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc 2003; 58: 41-49.
76. Liberato MJ, Canena J: Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. BMC Gastroenterol 2012; 12: 103.
77. Sangchan A, et al: Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc 2012; 76: 93-99.
78. Zoepf T, et al: Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430.
79. Gerhardt T, et al: Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z Gastroenterol 2010; 48: 28-32.
80. Pereira SP, et al: Photostent-02: porfimer sodium photodynamic therapy plus stenting alone in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours: a multicentre, randomised phase III trial. 2010 European Society for Medical Oncology Congress, Milan, October 8-12, 2010, abstract 802O.
81. Steel AW, et al: Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc 2011; 73: 149-153.
82. Shariff MI, Khan S, Westaby D: The palliation of cholangiocarcinoma. Curr Opin Support Palliat Care 2013; 7: 168-174.
83. NICE: Using radiofrequency energy to treat malignant bile or pancreatic duct obstructions caused by cholangiocarcinoma or pancreatic adenocarcinoma. 2013.
84. Llovet JM, Brú C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
85. Vogl TJ, et al: Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer 2011; 131: 733-740.
86. Scheuermann U, et al: Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma - a single-center experience. Eur J Surg Oncol 2013; 39: 593-600.
87. Valle J, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
88. Huggett MT, et al: Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom. Tumori 2014 (in press).
89. Knox JJ, et al: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23: 2332-2338.
90. Darwish Murad S, et al: Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98.
91. Nelson JW, et al: Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009; 73: 148-153.
92. Saito H, et al: Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008; 15: 63-68.
93. Kuvshinoff BW, et al: Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 1995; 82: 1522-1525.
94. Fletcher MS, et al: Treatment of hilar carcinoma by bile drainage combined with internal radiotherapy using iridium-192 wire. Br J Surg 1983; 70: 733-735.
95. McMasters KM, et al: Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997; 174: 605-608; discussion 608- 609.
96. González González D, et al: Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol 1999; 10(suppl 4):215-220.
97. Gwak HK, Kim WC, Kim HJ, Park JH: Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2010; 78: 194-198.
98. Pitt HA, et al: Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995; 221: 788-797; discussion 797-798.
99. Kim S, et al: Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002; 54: 414-419.
100. Nakeeb A, Pitt HA: Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford) 2005; 7: 278-282.
101. Huether A, et al: Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 2007; 73: 1308-1317.
102. Blechacz BR, Sanchez W, Gores GJ: A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol 2009; 25: 238-239.
103. Bengala C, et al: Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010; 102: 68-72.
104. Tournigand C, Malka D, Desrame J: 45th Congress of the American Society of Clinical Oncology (ASCO), Orlando, May 30-June 2 2009. J Chir (Paris) 2009; 146: 311-315.
105. Skipworth JR, et al: Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther 2011; 34: 1063-1078.